Skip to main content
GILD logo

GILD · Gilead Sciences, Inc.

Track GILD — free
$166.43 -0.10 (-0.06%) At close · Nov 20
Market Cap
$206.43B
Shares
1.24B
Volume · Nov 20 7.59M Avg daily vol (3M) 5.99M

Price & Indicators

 

Key stats

Close
$166.43
Fri 20 Nov
Open
$168.28
Fri 20 Nov
Average volume, 30 days
6.5M
shares a session
Short interest
21.3M
1.7% of shares · 3.2 days to cover
Day range
$165.80$170.24
Open $168.28 Close $166.43
52-week closing range
$118.30$174.48
Close $166.43 4.6% under the high
Short volume, last session
51%
Last earnings
Oct 29, 2026
Latest filing
10-Q · Oct 30
Price history
Jan 2020 to Nov 2026

Up next

Feb 9, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 10
Investor event
AnitaCell launch targets 80% center activation and 90% payer coverage

Gilead Sciences targets 80% of 200 authorized treatment centers activating within six months, 90% payer reimbursement within the first year and brand leadership within 18 months for AnitaCell. The earliest second-line filing is 2027.

4 source passages
Today, at launch for AnitaCell, we'll have 200 authorized treatment centers in the U.S. So we expect, again, six-month uptick of 80% of our authorized treatment centers coming on board. We also expect to have 90% of payers within the first year reimbursing. And, um, those are the types of things we're looking at. We are, you know, our goal is to achieve brand leadership within the first 18 months, and we're looking forward to doing that. And we're looking forward to bringing it forward in fourth line, and in 2027, it would be the earliest filing of the second line Open the document at this passage
Oct 30
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss of $6.0 billion after $11.3 billion acquired IPR&D

Gilead reported a nine-month net loss of $6.0 billion, driven by $11.3 billion in acquired IPR&D from acquisitions including Arcellx, Tubulis and Ouro Medicines.

Revenue $8.3B ▲ 6.8% Net income $2.43B ▼ 20.4% Diluted EPS $1.94 ▼ 20.2%
Read from the MD&A section
5 source passages
Net loss was $6.0 billion and diluted loss per share was $4.87 for the nine months ended September 30, 2026, compared to net income of $6.3 billion and diluted earnings per share of $5.04 for the same period in 2025. Acquired in-process research and development expenses were $11.3 billion for the nine months ended September 30, 2026, primarily related to the following transactions: $7.0 billion Arcellx acquisition; $3.1 billion Tubulis acquisition; $1.0 billion Ouro Medicines acquisition, comprised of $1.9 billion for our acquisition of Ouro Medicines, partially offset by $860 million related to Lakefront's share of the upfront consideration; Open the document at this passage
Oct 29
Earnings call
Base business sales rise 16% year-over-year in third quarter

Gilead's base business grew 16% year-over-year to $8.2 billion in the third quarter, and full-year base business sales guidance was raised to between $30.7 and $31 billion. CMS set Biktarvi pricing at $2,600 per 30-day supply, a net impact of approximately $1.5 billion on Biktarvi revenue expected in 2028.

4 source passages
As shown on slide 22, our base business grew 16% year-over-year to $8.2 billion, driven by continued growth across Biktarvi, Discovi, and Yeztugo in HIV, Tredelvian metastatic breast cancer, and Livdelzee in PBC, partially offset by lower sales of cell therapy products. We now expect base business sales to range between $30.7 and $31 billion. CMS has informed us that it has set pricing for BICTARV at $2,600 per 30-day supply, which represents an approximate 38% discount from the list price in the Medicare channel. we expect a total net impact to BikTarvi revenue of approximately $1.5 billion in 2028, reflecting the lower price in Medicare, in addition to related impacts across other U.S. channels, including Medicaid, 340B, and other payer segments. Open the document at this passage
Oct 29
Current report 8-K
Product sales rose 13% as loss guidance deepened

Gilead Sciences reported third-quarter 2026 product sales of $8.3 billion, up 13%, and raised full-year product sales guidance to $31,000-$31,300 million. Full-year GAAP diluted loss per share is now $(4.40)-$(4.05), while non-GAAP diluted loss per share is $(1.20)-$(0.85).

Financial results
5 source passages
Total third quarter 2026 product sales increased 13% to $8.3 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially offset by lower sales of Veklury® (remdesivir) and Cell Therapy products. For the full year 2026, Gilead now expects: Product sales | 31,000 | 31,300 | Previously $30,100 to $30,400 Diluted loss per share | (4.40) | (4.05) | Previously $(3.75) to $(3.40) Non-GAAP diluted loss per share | (1.20) | (0.85) | Previously $(0.65) to $(0.30) Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$30.99B
Trailing 12 months
Net income (TTM)
−$3.86B
Trailing 12 months
Revenue growth YoY
+6.8%
Year over year
Operating margin
-7.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
6.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$19.79B
Latest balance sheet
Dividend yield
2.0%
Trailing 12 months
Shares change YoY
-0.2%
Year over year · fewer shares
Price change (1Y)
+33.2%
Trailing year
Short interest
1.7%
Latest settlement · 3.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 29, 2026
Q3 FY26

TL;DR. Gilead delivered 16% base-business growth, strong HIV, prevention, Trodelvy and Livdelzi results, and raised full-year sales guidance. Principal headwinds are an expected $1.5 billion Biktarvy revenue impact in 2028, declining cell therapy and Veklury sales, higher expenses and acquisition-driven loss guidance.

Bullish
  • + Base business sales increased 16% year-over-year to $8.2 billion, representing the strongest growth in more than a decade.
  • + HIV sales increased 18% to $6.2 billion, driven by higher realized price, prevention demand and favorable inventory dynamics.
  • + HIV prevention sales nearly doubled year-over-year.
  • + Trodelvy sales increased 42% to $506 million on strong demand.
  • + Livdelzi sales increased 93% year-over-year and 21% sequentially to $203 million on increased U.S. and European demand.
  • + Gilead raised full-year base business sales guidance to $30.7 billion-$31 billion.
Bearish
  • − Gilead expects an approximately $1.5 billion net reduction to Biktarvy revenue in 2028 from Medicare pricing and spillover effects.
  • − Cell therapy sales decreased 18% to $355 million because of ongoing competitive headwinds.
  • − Veklury sales decreased 69% to $86 million because of lower COVID-19 hospitalization rates.
  • − GAAP diluted EPS declined to $1.94 from $2.43.
  • − Full-year non-GAAP diluted loss per share guidance worsened to $1.20-$0.85 from $0.65-$0.30 due to acquisition-related IPR&D charges.
  • − SG&A expenses increased to $1.6 billion on a GAAP basis and $1.5 billion on a non-GAAP basis, reflecting promotional, acquisition-integration, legal and employee-related costs.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +17%
above
Price vs 50-day avg +6%
above
RSI (14) 54
neutral
MACD trend Negative
52-week position 86%
near high
Momentum
relative strength
Very Strong
1-month return +7%
trailing
6-month return +30%
trailing
YTD return +36%
this year
Relative strength +40%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $157 › 200d $142 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +229 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.72% of shares out · ▲ +4.9% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
2,372 holders — near 3-yr high, broad support
Squeeze score 59
elevated · 0–100
Fundamentals
Excellent
Revenue growth +10%
Y/Y
EPS growth +1684%
Y/Y
Free cash flow $9.5B
Buyback $6.0B
authorized
Balance sheet $17.4B
net debt
Quant / Vol
risk profile
Moderate
Volatility 27%
annualized · 1-yr
Max drawdown −22%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 8
Latest guidance · from the 8-K filed Oct 29, 2026
full year 2026
Non-GAAP diluted loss per share Lowered $-1.20 – $-0.85
Aug 4, 2026 $8.50 – $8.85 changed to Oct 29, 2026 $-1.20 – $-0.85
2026 FULL-YEAR GUIDANCE
GAAP projected product gross margin Maintained 79%
Aug 4, 2026 79% changed to Oct 29, 2026 79%
Non-GAAP projected product gross margin Maintained 87%
Aug 4, 2026 87% changed to Oct 29, 2026 87%
Non-GAAP projected effective tax rate Raised 165% – 220%
Aug 4, 2026 115% – 140% changed to Oct 29, 2026 165% – 220%
Previous outlook earlier release · from the 8-K filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Product sales · For the full year 2026 $30.1B – $30.4B
Product sales excluding Veklury · For the full year 2026 $29.8B – $30.1B
Veklury · For the full year 2026 $300M
Diluted loss per share · For the full year 2026 $-3.75 – $-3.40
Guided vs delivered · last 8 settled
GAAP EPS full year 2025
guided $6.65 – $6.85
$6.78 In line
Diluted EPS full-year 2024
guided $5.15 – $5.55
$0.38 Miss −92.9%
Diluted earnings per share full-year 2023
guided $4.55 – $4.75
$4.50 Miss −3.2%
Total product sales full year 2023
guided $26B – $26.5B
$27.12B Beat +3.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+17% Bullish
Price vs 50-day avg
+6% Bullish
RSI (14)
54 Neutral
MACD trend
Negative Bearish
52-week position
86% Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $157 › 200d $142 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +229 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.72% of shares out · ▲ +4.9% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
2,372 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $118 Now $166 · 86% Range high $174
vs 200-day avg +17% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Free cash flow non-GAAP $5.86B Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GILD
Gilead Sciences, Inc.
this stock
$206.43B +35.6% +10.0% — 1.7%
LLY
ELI LILLY & Co
$1.27T +25.3% +44.7% 43.7 0.8%
JNJ
Johnson & Johnson
$651.11B +30.7% +6.0% 41.1 0.7%
ABBV
AbbVie Inc.
$505.89B +25.3% +8.6% 49.3 0.9%
MRK
Merck & Co., Inc.
$329.65B +27.0% +1.3% 137.9 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2,372
% held
86.7%
Net QoQ
-36.9M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,485
View
Short & Settlement
Short Interest Rising
Shares short
21.3M
Days to cover
3.2d
Change
+1.0M sh
View
Short Volume
Short vol %
51%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
425
Value
$66.3K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
37.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Jared Moskowitz
Amount
$1.0K–$15.0K
Traded
May 6, 2026
View
Financials
Financials
Revenue (FY)
$29.4B
Net income (FY)
$8.5B
EPS diluted
$6.78
View
Buybacks
Authorized
$6.0B
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
34
View
Proposed Sales
Value
$514.4K
Shares
3.0K
Filed
Nov 16, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Gilead Expands Access to Investig…
Published
Nov 16, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
GILD -1.0% +6.7% +30.5% -2.5% +35.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +7.6% +15.9% +39.6% +6.2% +34.4%

Capital returns

Latest dividend
$0.82 / share · ex Sep 15, 2026
Declared · upcoming
$0.82 / share · ex Dec 15, 2026
Raised 3.8%
Paid (TTM)
$3.25 / share · 4 payouts
Dividend yield (TTM, derived)
1.95%
Full dividend history
Buyback program · as of Aug 7, 2025
Authorized
$6.00B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 882095 CUSIP 375558103 13F (30d) 1978 filings 1842 filers Visit website Investor relations